Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compare / Semaglutide vs Orforglipron

Semaglutide vs Orforglipron

Semaglutide is available as a weekly injection and as tablets. Orforglipron is a daily pill that is not a peptide. How they differ in form, approvals and trial results.

Side-by-side facts · No recommendation · Reviewed

SemaglutideOrforglipronSame for both

SemaglutideOrforglipron
ClassGLP-1 receptor agonist (a peptide)Oral GLP-1 receptor agonist (a small molecule, not a peptide)
Brand namesOzempic, Wegovy, RybelsusFoundayo
FormsWeekly injection; daily tabletsDaily tablet
Approved forType 2 diabetes; chronic weight management; lowering cardiovascular risk (Wegovy pill)Weight management (approved April 1, 2026)
Type 2 diabetesApprovedFDA decision expected in late 2026
Average weight loss in trialsAbout 15% in the STEP 1 trial (injection)Up to about 11% over 72 weeks
Boxed warningThyroid C-cell tumors (rodent data)Thyroid C-cell tumors (class warning)

The trial numbers

Average weight loss in the STEP 1 trial of semaglutide injection was about 15%. In orforglipron trials it was up to about 11% over 72 weeks, which is less than the leading injectable drugs.

The figures come from different trials with different designs, so they cannot be compared directly. They show the size of the effect in each trial, not which drug is better for a person.

Key differences

Orforglipron is a small molecule, not a peptide, and it is taken as a daily pill. Semaglutide is a peptide. Its main forms are a weekly injection and, more recently, daily tablets.

Semaglutide has several approvals, including type 2 diabetes. Orforglipron was approved as Foundayo for weight management on April 1, 2026, and a type 2 diabetes decision is expected in late 2026.

What they share

Both act on the GLP-1 receptor, and both carry the class boxed warning about thyroid C-cell tumors. Stomach and bowel side effects are the most common for both.

Questions

Is orforglipron a peptide?

No. It is a small molecule that acts on the GLP-1 receptor and is taken by mouth. Semaglutide is a peptide.

Does orforglipron come as an injection?

No. It is a daily pill, so there is nothing to draw up or measure with a syringe.

Which one works better?

The trials used different designs, so their results cannot be compared directly. Which drug suits a person is a decision for them and their prescriber.

Which compound, if any, suits a person is a decision for them and a licensed prescriber. This page compares published facts and does not recommend either.

Sources: Managed Healthcare Executive: GLP-1 pills; GoodRx: GLP-1 trends; Prime Therapeutics: GLP-1 pipeline update, August 2026; Novo Nordisk: Wegovy and Saxenda safety information; Polsinelli: FDA compounded GLP-1 policy; Ro: do GLP-1 pills work.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.